Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 1.00 |
| ▸ | AKT1 | P31749 | 2/20 | 0.83 |
| ▸ | AKT2 | P31751 | 2/20 | 0.83 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30081800 | 1.00 | PIK3CA (1.00) | PIK3CAAKT1AKT2AKT3 | |
| SCHEMBL25531613 | 0.94 | PIK3CA (0.88) | PIK3CAAKT1AKT2AKT3 | |
| SCHEMBL25532460 | 0.94 | PIK3CA (0.88) | PIK3CAAKT1AKT2AKT3 | |
| SCHEMBL25532466 | 0.92 | PIK3CA (0.85) | PIK3CAAKT1AKT2AKT3 | |
| SCHEMBL25531614 | 0.92 | PIK3CA (0.85) | PIK3CAAKT1AKT2AKT3 | |
| SCHEMBL30081618 | 0.91 | AKT1 (1.00) | PIK3CAAKT1AKT2AKT3 | |
| SCHEMBL25181878 | 0.91 | AKT1 (1.00) | PIK3CAAKT1AKT2AKT3 | |
| SCHEMBL30307557 | 0.91 | AKT1 (1.00) | PIK3CAAKT1AKT2AKT3 | |
| SCHEMBL23896265 | 0.91 | AKT1 (1.00) | PIK3CAAKT1AKT2AKT3 | |
| SCHEMBL27383209 | 0.91 | AKT1 (1.00) | PIK3CAAKT1AKT2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286960-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230286960-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230286960-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-09-14 | — | — | US | disclosed |
| US-11649227-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649227-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649227-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2023-05-16 | — | — | US | disclosed |
| WO-2021202964-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH P13K MODULATION | PETRA PHARMA CORPORATION (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286960-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, AKT3, PIK3R1 | PIK3CA 1/4885AKT1 6/4885AKT2 16/4885 |
| US-11649227-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PIK3CA, AKT3, PIK3R1 | PIK3CA 1/4885AKT1 6/4885AKT2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.